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Innate-immune pattern-recognition-receptor TLR3 is critical for sensing RNA-
viruses, and triggering transcription of potent antiviral type-I interferons. While 
ubiquitination is well known to regulate interferon response, a genome-wide 
understanding of the role of ubiquitin ligases in TLR3 signaling is yet to be 
generated. To fill this knowledge-gap, the effect of ectopic expression of the 
human ubiquitin ligases and their adaptors (UBL/A) encoded in human 
genome on TLR3 mediated type-I interferon b (IFNb) response was assessed. 
In the first part of the study, HEK293T cells over-expressing each one of the 
UBL/A genes were generated, stimulated with TLR3 ligand Poly (I:C), and the 
IFNb gene transcription was determined using IFNb gene promoter driven 
GFP-reporter. Microscopy based data collection and analysis identified novel 
positive or negative regulator UBL/A genes of IFNb production. An over-
expression screen was then carried out to identify the genes that regulate the 
IFN production by modulating the cellular level of TLR3. The capacity of the 
identified gene to regulate IFNb response was subsequently validated with a 
gene knock-down approach. Finally, the mechanism by which one selected hit 
gene (TRAF4) regulates the IFN response was investigated. It was 
determined that TRAF4 interacted with TLR3, and promoted degradation of 
the TLR3. Furthermore, Sendai virus infection resulted in transcriptional 
upregulation of TRAF4. In summary, this thesis identified TRAF4 as a 
negative regulator of TLR3 mediated interefron response, throught the 
ergulation of TLR3 protein turnover. Thus, this study generated both a novel 
global as well as specific mechanistic understanding of the role of UBL/A 




Innate immunity- An overview  
 
The innate immune system constitutes the first line of defence against 
invading pathogens. In principle, it consists of the physical and chemical 
defence and the cellular defence. The physical defence is basically a physical 
barrier to block the entry pathogens, thereby prevents pathogens from 
crossing epithelia and colonizing in tissues, while the chemical defence clears 
the pathogens by degrading them with chemical substances. The cellular 
component of the innate immune system is more complex, and consists of 
various types of myeloid cells, which are professional immune cells that 
function to engulf and clear pathogens from the host. (Medzhitov & Janeway, 
2000) These cells can perform their functions on their own, such as in the 
case of neutrophils which are sufficient on their own to destroy bacteria. 
(Mayadas, Cullere, & Lowell, 2014) On the other hand, these cells can also 
act in conjunction with one another or with the components of the adaptive 
immune system. For instance, antibodies opsonize pathogens and mark them 
for ingestion by myeloid cells. (Gasteiger & Rudensky, 2014) 
 
Myeloid cells mentioned above can be broadly classified into two classes: 
mononuclear phagocytes and polymorphonuclear phagocytes. (Yan & 
Hansson, 2007) Mononuclear phagocytes include macrophages and dendritic 
cells, which originate from monocytes. (Gordon & Mantovani, 2011) 
Macrophages constitute a functionally important population of phagocytes that 
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are capable of phagocytosis, a process through which pathogens are 
internalized and destroyed. More precisely, after the internalization of the 
pathogen, phagosome containing various reactive oxygen species and 
hydrolytic enzymes are formed to destroy the engulfed pathogens. (Vernon & 
Tang, 2013) Also, macrophages can secrete different chemotactic cytokines 
to recruit other kinds of phagocytes to the site of infection to coordinate the 
overall immune response. (Poon, Ho, Chiu, & Chang, 2013) Dendritic cells, as 
one of the members of the professional antigen-presenting cells, act in a 
similar fashion to gather the other classes of phagocytes to initiate an immune 
response. The do so by taking up and destroying the pathogens by 
phagocytosis. The pathogens are then digested into small peptides, further 
processed and displaying the antigens on class II MHC proteins to present 
them to CD4+ T cells. On the other hand, dendritic cells also present antigens 
to CD8+ T cells via class I MHC or cross presentation. (Mildner & Jung, 2014)  
 
The polymorphonuclear phagocytes, on the other hand, work in a more 
independent manner. The short-lived yet highly motile neutrophils, are 
responsible for destroying pathogens by phagocytosis and degranulation, a 
process through which the granules with anti-microbial properties are 
released to combat pathogens. (Wang & Arase, 2014) Eosinophils and 
basophils are found more rarely than neutrophils, and are mainly responsible 
for releasing inflammatory mediators to regulate inflammation. (Geering, 
Stoeckle, Conus, & Simon, 2013)  
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To distinguish foreign from self-molecules, the innate immune system 
employs a strategy to recognize features associated with a broad class of 
pathogens that are absent in host molecules with a limited number of 
molecular sensors. (Tang, Kang, Coyne, Zeh, & Lotze, 2012) These features, 
also known as pathogen-associated molecular patterns (PAMPs), are 
essential for the survival and/or pathogenicity of the pathogens, and so are 
evolutionarily conserved and not easily altered by mutation or selection. (Paul 
& Grossman, 2014) Primarily speaking, the detection of PAMPs is carried out 
by germline-encoded pattern-recognition receptors (PRRs). After identifying 
the invading pathogens by the PRRs, the innate immune system responds to 
remove the infectious pathogens by employing complement activation and 
initiating phagocytosis and autophagy by the various immune cells mentioned 
above. (Kumar, Kawai, & Akira, 2011)  
 
Pattern recognition receptors - how viruses are recognized as foreign by 
the immune system   
 
Pattern recognition receptors (PRRs) can be broadly classified into two types 
based on their cellular localization: Membrane-bound receptors including toll-
like receptors (TLRs) and C-type lectin receptors (CLRs) recognize PAMPs 
that are generally associated with extracellular pathogens such 
as lipoproteins, lipopolysaccharide (LPS), flagellin and peptidoglycan present 
in bacteria. (Tang et al., 2012) Cytoplasmic receptors such as NOD-like 
receptors (NLRs), pyrin and HIN domain-containing (PYHIN) family members, 
RIG-I-like receptors (RLRs) and other cytoplasmic nucleic acid sensors are 
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more steered towards recognizing features commonly associated with 
intracellular pathogens such as viral nucleic acids. (Suresh & Mosser, 2013)  
Toll-like receptors are one of the best characterized families of PRRs. They 
are evolutionarily conserved and can be classified into three main categories, 
namely Toll-like receptors (TLRs), RIG-I-like receptors (RLRs) and Nod-like 
receptors (NLRs). Up till now, 13 TLRs have been identified. (Kawai & Akira, 
2011) All these TLRs consist of an extracellular domain which is made up of 
leucine-rich repeats that are responsible for PAMP recognition, a 
transmembrane domain and a conserved cytoplasmic toll/IL-1 receptor 
domain (TIR), which mediates the interaction with downstream signalling 
molecules. (Uematsu & Akira, 2006) TLRs are located at different cellular 
compartments for sensing pathogens from different sources: in humans, 
TLR3, TLR7, TLR8 and TLR9 are found on intracellular compartments such 
as the endoplasmic reticulum and endosome, and are responsible for 
recognizing viral nucleic acids; while the other TLRs, like TLR1, TLR2, TLR4, 
TLR5 and TLR6 are localized on the cell surface to recognize mainly bacterial 
cell wall components.  (Uematsu & Akira, 2008) Figure 1 summarizes the 




Figure 1: TLR 1-9 and their respective ligands. Those that are located n cell 
membrane recognized extracellular pathogen-derived molecules, while those 
that are located in endosomal membrane recognize intracellular pathogen-
derived molecules.  
 
Virus receptors  
 
Among all the identified TLRs, a subset is important for detecting PAMPs 
found in viruses and plays a critical role in anti-viral defense, and it includes 
TLR3, TLR7/8, and TLR9. Of these, TLR3 is specifically responsible for 
recognizing double-stranded RNA structures which are found commonly in 
RNA viruses, especially in retroviruses. (Perales-Linares & Navas-Martin, 
2013). It is expressed in immune cells including macrophages and 
conventional dendritic cells, as well as in non-immune cells such as epithelial 
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cells and fibroblasts. Upon pathogen recognition, TLR3 signals through an 
important downstream molecule, TRIF, to induce the phosphorylation of the 
transcription factor IRF3. After that, the phosphorylated IRF3 translocates into 
the nucleus to initiate the expression of type-I interferons, which are critical in 
the defence against viruses. (Matsumoto, Oshiumi, & Seya, 2011)  
 
 
Figure 2: Major players in the TLR3-mediated signalling.  
 
Another class of PPRs, the RLRs (RIG-I-like receptors), are responsible for 
sensing PAMPs present in viral RNA in the cytoplasm. Up to present, there 
are three members of the RLRs identified, namely RIG-I (retinoic acid-
inducible gene I), MDA5 (melanoma differentiation associated factor 5) and 
LGP2 (laboratory of genetics and physiology 2). (Schlee, 2013)  
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Among these, RIG-I has been studied most extensively. The structure of RIG-
I can be broadly divided into three parts: the N-terminal region containing 
tandem caspase activation and recruitment domains (CARD), the middle 
DExD/Hbox RNA helicase domain which is responsible for hydrolyzing ATP to 
supply energy for binding and unwinding RNA and the C-terminal domain 
consisting the repressor domain which takes part in auto-regulation. 
(Yoneyama & Fujita, 2007) The ligand of RIG-I is typically 5’ triphosphate 
dsRNA. Upon recognition of the ligand, RIG-I signals through a cascade of 
molecules that can also be found in other cellular immune pathways, such as 
IPS-1, TRAF3, TBK, IRF3 and 7. The end result is the production of interferon 
α and β. (Yoneyama & Fujita, 2009)  
 
TLR signalling pathways  
 
The recognition of different PAMPs by various TLRs causes distinctive 
responses due to the up-regulation of distinct sets of genes. (Beutler, 2004) 
Upon recognition of PAMPs, different TLRs recruit different TIR-domain 
containing adaptor molecules such as MyD88, TIR domain-containing adaptor 
inducing IFN-β (TRIF; also known as TICAM-1), TIRAP/Mal, TRIF-related 
adaptor molecule (TRAM), and Sterile-alpha and Armadillo motif-containing 
protein (SARM) and result in the activation of different signalling pathways. 
These pathways can be generally divided into MyD88-dependent and TRIF-
dependent. (Beutler, 2004) The two pathways are summarized in figure 3. 
(adopted from Patel et al., 2012)  
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MyD88 is an adaptor molecule that comprises a death domain and a TIR 
domain. It bridges signals between many TLRs (except TLR3) and a series of 
important downstream molecules. (Janssens & Beyaert, 2002) Upon 
activation, MyD88 recruits IRAK4, which in turn recruits other IRAKs, mainly 
IRAK1 and IRAK2. These IRAKs then dissociate from MyD88 and interact 
with TRAF6, an E3 ubiquitin ligase. Together with an E2 ubiquitin-conjugating 
enzyme, it catalyzes the formation of lysine 63 (K63)-linked polyubiquitin 
chain on TRAF6 itself plus an unconjugated free polyubiquitin chain. This 
unconjugated free polyubiquitin chain then activates a complex consisting of 
TAK1, TAK1-binding protein 1 (TAB1), TAB2, and TAB3 leading to the 
phosphorylation of IκB kinase (IKK)-β and MAP kinase kinase 6. This brings 
about the phosphorylation of IκBa, an NF-κB inhibitory protein by the IKK 
complex. The phosphorylated IκBa is degraded by the ubiquitin-proteasome 
system, and one of its components, NF-κB, is released and translocates into 
the nucleus and activates expression of genes of pro-inflammatory cytokines. 
As this pathway is responsible for the production of pro-inflammatory 
cytokines, individuals with MyD88 deficiency suffer from recurrent pyogenic 
bacterial infection. (Warner & Nunez, 2013)  
 
The other pathway which is MyD88-independent depends on TRIF. TLR3 
employs this pathway exclusively to activate the expression of pro-
inflammatory cytokines, and TLR4 uses this pathway occasionally. (Piras & 
Selvarajoo, 2014) To over simplify the pathway, the immediate signalling 
molecule downstream of TLR3, TRIF, recruits TRAF6. In turn TAK1 is 
recruited to activate the downstream MAPKs and finally NF-κB. On the other 
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hand, it recruits also RIP1 through its RIP homotypic interaction motif. RIP1 
then undergoes K63-linked polyubiquitination and consequently results in NF-
κB activation. Beside NF-κB activation, TRIF also mediates the expression of 
Type-I IFN by recruiting signalling molecules including TRAF3 and then the 
non-canonical IKKs TBK1 and IKKi (IKKε) that catalyze the phosphorylation of 
IRF3 and lead to its nuclear translocation. (Yamamoto et al., 2003) 
 
 








Interferons are the powerful weapons that the immune system uses to defend 
the host from viral attack. They are secreted as cytokines and can be 
generally grouped into three classes, based on their amino acid sequence: 
Type I, Type II and Type III. (Giorgio Trinchieri & Perussia, 1985) Type I IFNs 
are encoded by a large group of different IFN genes, including those which 
are stimulated directly by viral infections like IFN α/β, and those that play 
some other roles such as IFN-ω, -ϵ, -τ, -δ and -κ. (G. Trinchieri, 2010) Type II 
IFN has only one member, IFN-γ, secreted by activated T cells and natural 
killer (NK) cells. IFN-γ plays many roles in immunity, owing to its anti-viral and 
anti-tumor properties. (Boehm, Klamp, Groot, & Howard, 1997)  
 
All members of the Type I IFN family bind to the type I IFN receptor, typically 
located on cell surface. This receptor is composed of two subunits, IFNAR1 
and IFNAR2. (Platanias & Fish, 1999) Upon activation, theses two subunits 
signal through Janus activated kinases (JAKs) tyrosine kinase 2 (TYK2) and 
JAK1 which are constitutively associated to them. This results in the tyrosine 
phosphorylation of STAT2 (signal transducer and activator of transcription 2) 
and STAT1, and subsequently the formation of STAT1–STAT2–IRF9 (IFN-
regulatory factor 9) complexes, which are also called ISGF3 (IFN-stimulated 
gene (ISG) factor 3) complexes. The complexes are then translocated into the 
nucleus to bind to the IFN-stimulated response elements (ISREs) found in the 
promoter of genes and to initiate transcription of the IFN-stimulated genes 
(ISGs). (Goodbourn, Didcock, & Randall, 2000) Similarly, type II IFNs also 
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bind to a receptor that consists of two subunits, IFNGR1 and IFNGR2, which 
are constitutively associated with JAK1 and JAK2. However upon activation 
instead of the STAT-1-STAT2 complexes, the STAT-1-STAT1 complexes are 
formed, which are then translocated into the nucleus to bind to the GAS 
elements on DNA to initiate the transcription of another set of ISGs, which is 
also partially overlapping with those inducible by type I IFN. It is worthwhile to 
note that the activation of type I IFN receptor can also lead to the formation of 
STAT1-STAT1 homodimers and activates transcription through binding to the 
GAS element. (Platanias, 2005) Figure 4 depicts the key signalling events 
downstream of IFN receptors. (adopted from Platanias et al., 2005)   
 
 
Figure 4: Key signalling events downstream of IFN receptors.  
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The expression of ISGs varies in level and type across different cell types, in 
response to different stimuli. (Schneider, Chevillotte, & Rice, 2014) The 
products of these ISGs exert a variety of anti-viral effects and can target 
different steps of the viral cycle, such as entry, uncoating, transcription, 
translation, assembly and egress. Specific functions of these ISGs products 
can differ significantly. (Sen & Sarkar, 2007) For instance, one class of ISGs, 
the IFIT proteins, which are the most inducible by IFN and virus treatment, is 
mainly responsible for restricting with virus replication through interfering viral 
protein synthesis. (Zhou et al., 2013) On the other hand, another important 
ISG product, viperin, exerts its anti-viral effects through many ways, such as 
interacting directly with different host and viral proteins to interfere with viral 
replication and interacting with host organelles like ER and lipid droplets 
which serve as the scaffold for viral assembly. (Helbig & Beard et al., 2014)  
 
Other ISG products, however, regulate the expression level of the other ISG 
products both positively and negatively. In short, the ISGs encode a large set 
of proteins that have different anti-viral effects, with the aim of preventing viral 









The ubiquitination mediated regulation of cell signalling    
 
The ubiquitin ligases and ubiquitination   
 
Ubiquitination is a post translational modification of proteins. Ubiquitination 
regulates multiple aspects of protein functioning such as stability, signalling 
complex formation or dissociation etc.    
 
Ubiquitination is the process by which a small (around 8.5kDa) regulatory 
molecule called ubiquitin is added onto targeted proteins to mark them for 
digestion by the 26S proteasome. (Callis, 2014) This process of tagging 
ubiquitin to intracellular substrates ensures that the biological system can 
keep track of the use of proteins by controlling the half-life and expression 
level of proteins, and by getting rid of those that accumulate in the cells to 
remove excessive cellular response. (Wilkinson, 2000) On the other hand, 
ubiquitin conjugation to cell surface receptors can cause down-regulation of 
them through the endosomal-lysosomal pathway. (Lowe, Doherty, Karahashi, 
& Arditi, 2006) Likewise, ubiquitination also plays an important role in 
processing foreign molecules in antigen-presenting cells to facilitate immune 
responses. (Cho & Roche, 2013) However, in some cases, ubiquitination 
does not contribute to the fate of proteins. (Petroski, 2008) Certain non-
proteolytic processes are associated with the addition of one single ubiquitin 
to the protein molecule (monoubiquitination) or some specific type of 
polyubiquitination. These processes can affect the sub-cellular localization or 
the functions of the proteins. Also, these processes can be reversed by 
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enzymes called deubiquinases which function by removing the ubiquitin from 
the labelled proteins. (Chen & Sun, 2009)    
 
The process of ubiquitination   
 
The process of ubiquitination can be divided into three steps:  First, the 
targeted protein is activated by E1, the ubiquitin-activating enzyme, at the 
expense of ATP-driven energy. (Jin, Li, Gygi, & Harper, 2007) The E1 enzyme 
binds to ATP and ubiquitin, catalyzing the acyl-adenylation of the C-terminus 
of the ubiquitin molecule. After the formation of this ubiquitin-adenylate 
intermediate, the ubiquitin is transferred to the active site cysteine residue, 
releasing AMP from the intermediate. The result is the generation of a 
thioester bond between the C-terminus of the carboxyl group of ubiquitin and 
the sulfhydryl group of the cysteine residue of the E1 enzyme. (Pickart, 2001) 
Then, the E2, the ubiquitin-conjugating enzyme, kicks in to bind to both the E1 
and the ubiquitin and transfer the ubiquitin from E1 to the active site cysteine 
of itself, through a trans(thio)esterification reaction. (Scheffner, Nuber, & 
Huibregtse, 1995) The last step of the process involves E3, the ubiquitin 
protein ligase, which serves as a substrate recognition module and interacts 
with both E2 and substrate. The ligation reaction involves the formation of an 
isopeptide bond between the lysine of the target protein and the C-terminal 
glycine of ubiquitin. (Das et al., 2013)    
 
The ubiquitin molecule harbours 7 lysine residues, at K6, K11, K27, K29, K33, 
K48 and K63. Theoretically the polyubiquitin chain can be formed on anyone 
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of these. (Dikic, Wakatsuki, & Walters, 2009) However, most of the findings 
up-to-date suggest that proteasomal degradation occurs when 
polyubiquitination utilizes K48 as the conjugating lysine, as it is recognized by 
the 26S proteasome. (D. Komander, 2009) On the other hand, K63 linked 
ubiquitination is suggested to have non-proteolytic functions. Some studies 
pointed out that K63 linked ubiquitination does not lead to protein degradation 
in vivo, although some other suggested that it may facilitate proteasome 
dependent protein degradation. (In vitro assembly and recognition of Lys-63 
polyubiquitin chains.) Ubiquitination involving other lysine residues have also 
been observed, however their roles are less understood. Studies suggested 
that they take part in either protein degradation or non-proteolytic functions. 
(Pickart & Eddins, 2004)  Figure 5 shows the process of ubiquitination. 
(Matyskiela, Rodrigo-Brenni, & Morgan, 2009)  
 
 
Figure 5: The process of ubiquitination.  
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General structures and functions of E3 UBL    
 
A large group of E3 ubiquitin ligases is called the HECT domain E3s, which as 
suggested by the names, contain a HECT domain. This domain is located at 
the C-terminus and is about 350 amino acids long. The HECT domain 
consists of two lobes, one at the N-terminus which interacts with E2 and the 
other one at the C-terminus which contains the active-site cysteine that forms 
thioester bond with ubiquitin. The N-terminus is however, more diverse and is 
engaged in substrate recognition. (Ardley & Robinson, 2005)    
 
Another large group of ubiquitin ligases is the RING finger E3 ligases. The 
RING domain contains specifically spaced cysteine and histidine residues and 
is arranged in a way that mediates the harboring of a zinc ion. It is responsible 
for facilitating E2-dependent ubiquitylation. Instead of forming a catalytic 
intermediate with E2 like the HECT E3s, the RING finger E3s serve as a 
scaffold for the E2 and the substrate to interact. (Deshaies & Joazeiro, 2009)    
 
Role of UBLs in regulation the TLR3-mediated signalling pathway - knowledge 
gaps   
 
The complex signalling network involved in TLR3 activation and the 
expression of pro-inflammatory cytokines is highly regulated by the 
degradation of the signalling molecules involved, so that over-activation of 
inflammation and potential harm to the host can be prevented. (Lowe et 
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al.,2006) UBLs play an important role in targeting the used or over-expressed 
signalling molecules for proteasomal degradation. (Malynn & Ma, 2010)  
 
Several ubiquitin ligases such as TRIM38 and WWP2 were reported to target 
TRIF for degradation, thereby negatively regulating TLR3-mediated innate 
immunity and inflammatory response. (Xue et al., 2012) (Yang et al., 2013) 
The modulatory action of these ubiquitin ligases is important as excessive 
production of type I IFNs can lead to uncontrolled deleterious medical 
conditions such as sepsis and autoimmune diseases.  (Lowe et al., 2006)  
 
On the other hand, some ubiquitin ligases contribute positively to the TLR3 
mediated production of IFNs. Pellino-1 is responsible for the ubiquitination of 
RIP1, one of the adaptor proteins upstream of NF-κB. Deficiency of Pellino-1 
was reported to cause failure to respond to TLR3 agonists, even if there was 
normal MyD88-dependent NF-κB activation. (Enesa et al., 2012) Collectively, 
ubiquitin ligases play an important role in fine-tuning the TLR3-mediated 
signalling to keep the production of IFN under control. (Isaacson & Ploegh, 
2009)  
 
Although some studies have shed light on the role of ubiquitination in TLR3 
regulation, a comprehensive understanding of the role of ubiquitin ligases and 
genes promoting ubiquitination (e.g., adaptors of ubiquitination) in TLR 
mediated IFN response is not available till date. Particularly, till now, only very 
few studies have evaluated the role of ubiquitin ligases in the regulation of 
type-I Interferon production at the level of the membrane receptor TLR3.  
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Goals of this thesis   
 
Our unpublished studies identified several novel ubiquitin ligase and their 
adaptor proteins encoded as regulators of TLR3 triggered IFNb transcription, 
through the over expression of most of the ubiquitin ligases and adaptors 
present in the human genome. In this thesis, the previously identified UBLs 
and their adaptors that showed regulatory effects on IFNb production were 
validated, and one of these previously identified (and unpublished) TLR3 
regulator ubiquitin ligase, TRAF4, was characterized in detail on how it 

















Materials and Methods    
Reagents    
The cell lines used, namely HEK 293 T and HCT 116 were purchased from 
the American Type Cell Collection (ATCC, Manassas, VA). Dulbecco's 
Modified Eagle's Medium (DMEM) and the medium supplement fetal bovine 
serum (FBS) are purchased from Invitrogen. As for the competent cells, DH5α 
bacterial cells were obtained from Invitrogen, California, and XL10-Blue cells 
were prepared by me. Luria-Bertani (LB) broth and agar were bought from 
Becton Dickinson, USA. QIAGEN Plasma Maxi Kits were from Qiagen, 
Singapore. Nuclease-free water was from Thermo Scientific, Utah. All siRNA, 
siRNA buffer and DharmaFECT® 1 were purchased from Thermo Scientific 
(USA). Poly(ethyleneimine) (PEI) was from Sigma-Aldrich, USA. Flag-TRIF, 
Flag-TLR3, Myc-TBK1, IRF3 D5 and pGL4.2-IFN-GFP plasmids were 
obtained from Addgene, USA.     
 
Cell culture    
HEK 293 and HCT 116 cells (ATCC, Manassas, VA) were maintained in 
DMEM (Invitrogen, Auckland) supplemented with 10% FBS (Invitrogen, South 
America), on 10cm tissue culture dishes. The cells were incubated at 37°C, 
5% CO2 in a CO2 incubator and passaged when 80% confluency was 
reached.         
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Plasmid Transformation into bacterial cells   
Flag-TLR3, Flag-TRIF and the UBL plasmids (Addgene, USA) on filter papers 
were dissolved in 6Pl of milli-Q water. DH5α competent bacterial cells 
(Invitrogen, California) were used for transformation. The competent cells 
were incubated with the plasmids on ice for 30 min, after which heat shock 
treatment at 42°C for 2 min were given to the cells. Then it was followed by a 
cold shock treatment at 0°C for 2 minutes. Then the cells were incubated with 
500ul of LB broth (Becton Dickinson, USA) at 37°C with shaking for 1 hour. 
100ul of the transformed cells were plated overnight on separate LB agar 
(Becton Dickinson, USA) plates with either 50pg/ml of Ampicillin or 25pg/ml of 
Kanamycin to select for the transformants.      
 
Plasmid Isolation     
A single colony of transformed cells on LB agar plate was inoculated into 10ml 
of LB broth and shaken overnight for mini-prep scale preparation, and in 50ml 
of LB for midi-prep scale of preparation. Cells were pelleted by centrifugation 
at 6000xg for 15 minutes, and total plasmids were isolated by QIAGEN 
Plasma Mini/ Midi Kits (QIAGEN, Singapore) according the manufacturer’s 
protocol. The plasmid DNA eluted was dissolved in 50ul and 200ul of 
nuclease- free water (Thermo Scientific, Utah) in the case of Mini-prep and 
Midi-prep respectively. The prepared plasmids were quantified using 
Nanodrop 2000 spectrophotometer.         
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Optimization of siRNA transfection    
siPLK1 was used to  optimize transfection of 293T cells, taking advantage of 
its well-established ability to cause visible cell death. siPLK1 (Thermo 
Scientific, USA) was resuspended in 1x siRNA buffer to give a range of 
concentrations between 30nM and 60nM, in a final volume of 10ul. These 
were incubated with 0.05ul of DharmaFECT® 1 (Thermo Scientific, USA) in 
10ul of Serum Free Medium (SFM) (Invitrogen, Auckland) for 30 minutes to 
allow formation of siRNA-lipid complexes. HEK 293 T cells (3 x 103 cells per 
well) suspended in 20ul of DMEM supplemented with 20% FBS were added 
to the complexes. Cells were incubated at 37°C, 5% CO2 in a CO2 incubator 
and the cell death and morphology were monitored over a course of 72 hours 
to determine the optimal time point for measuring the signal output.     
 
Validation of knock-down efficiency of siRNA     
Two siRNA were purchased from SAbio, Singapore. The sequence of the two 
siRNA are as followed: siTRAF4-2: CACCAGCACATTCGAAAGCGA; 
siTRAF4-5: AAGCTGGAAGTACAAGTATTG. The knockdown efficiency was 
tested by over-expressing TRAF4 and then knocking down by the two siRNA.  
HEK 293 T cells were plated on 6-well plates, and were subsequently 
transfected with TRAF4 at 500ng/well. The cells were incubated at 37C for 5 
hours. Then the cells were transferred to a 12-well plate with 3ul of the siRNA 
(20uM), 47ul of siRNA buffer, 3ul Dharmafect 1 reagent and 47ul of serum 
free DMEM mixed thoroughly in each well. The cells were incubated for 30 
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minutes at 37C for transfection to occur. After transfection, the cells were 
lysed and the lysate was analyzed by immunoblotting, to determine whether 
the siRNA can knock down the transfected TRAF4 plasmid.   
  
Reporter assays    
The reporter assays were performed as described in the validation of the 
siRNA knock-down efficiency. Briefly, HEK 293 T cells were transfected with 
expression plasmids of human TLR3 (pUNO vector) and the human IFNb 
promoter driven GFP reporter (pGL4.2 vector) for 24 hr. Cells were then 
stimulated with poly (I:C) by adding to the medium (20 µg/ml) for additional 18 
hr, and the images of the cells were captured under the fluorescence 
microscope (Olympus 1X71).    
 
RNA isolation    
RNA was extracted from cells with Trizol according to the manufacturer’s 
protocol. In brief, cells grown on 24-well plates were lysed with Trizol reagent 
and chloroform was added and the mixture was vortexed thoroughly. The 
aqueous and the non-aqueous phases were further separated by 
centrifugation. The aqueous phase was isolated and the RNA within it was 
precipitated using isopropanol. The RNA pellet was washed a few times with 
ethanol and then resuspended in DEPC-treated water. The dissolved RNA 
was quantified by measuring the absorbance at 260 and 280nm with the 
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NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA), and with the A260/A280 ratio at around 1.8 to 2.0 
being an indicator of high purity of the RNA isolated.       
 
cDNA synthesis    
cDNA was prepared using  iScript™ cDNA Synthesis Kit (Bio-Rad 
Laboratories, Inc.) according to the user manual. In brief, the RNA template 
was incubated with reverse transcriptase, the reverse transcriptase buffer and 
nuclease-free water at 25°C for 5 min and then at 42°C for 30min. The cDNA 
was then stored at -20°C.    
 
Quantitative real-time PCR   
The expression of TRAF4 mRNA was determined by quantitative real-time 
PCR, It was performed in an optical 96-well plate with the LightCycler® 480 
Real-Time PCR System (Roche). A double strand DNA intercalating 
fluorescence dye, SYBR green (iQ™ SYBR® Green Supermix #170-8880, 
BioRad) was used to monitor the dsDNA amplification and to calculate the 
product per reaction cycle. Each reaction was 25ul in volume and consisted of 
300nM of both the forward and reverse primers, an amount of cDNA template 
that was equivalent to 100ng of RNA, nuclease-free water and the iQ™ 
SYBR® Green Supermix (#170-8880, BioRad). The plate was sealed with a 
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thermal-adhesive film to prevent content loss due to evaporation during the 
reaction at high temperatures. The amplification conditions were as follows:        




Initial denaturation and 
enzyme activation 
95°C 2:00-3:00 1 
Denaturing 95°C 0:10-0:15  
Annealing 55°C 0:15-0.30 40 
Extension 72°C 0:30  




Preparation of cell lysate and Immunoblotting    
For the over-expression experiments, HEK 293 T and HCT 116 cells were 
lysed in RIPA buffer (10 mM Tris-Cl at pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 
1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS and 140mM NaCl), 
supplemented with 1X Halt Protease and Phosphatase Inhibitor Cocktail 
(Thermo Fisher Scientific Inc.). Protein lysates were centrifuged at 13.5K rpm 
to pellet the insoluble debris and were transferred to fresh tubes and mixed 
with 5X loading dye (0.25% bromophenol blue, 0.5M DTT, 50% glycerol, 10% 
SDS and 0.25M Tris-Cl at pH 6.8). As for samples obtained from co-
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immunoprecipitation experiments, the input samples were collected using 
RIPA buffer likewise, and the IP samples were collected by 5X SDS loading 
dye.    
Proteins within the lysates were separated by SDS-PAGE. In brief, cell lysates 
with loading dye were loaded on polyacrylamide gels of either 7.5% or 10%, 
depending on the size of proteins to be detected. The gels were run with 80V 
to separate proteins according to their different size. The proteins were then 
transferred onto PVDF membranes (162-0177, BioRad), pre-wet with 
methanol. The membranes were subsequently probed with primary antibody 
and secondary antibody, diluted with either 5% skim milk or 5% BSA in TBST. 
All secondary used for immunoblotting were conjugated with fluorochrome of 
either 680 nm or 800 nm. Infrared fluorescent bands were detected by LICOR 
Odyssey™ IR imager.     
 
Co-immunoprecipitation    
HEK 293 T cells were seeded into 6-well plates (1 million cells per well) 24 h 
before transfection. Cells in each well were then transfected with 500ng of 
either the V5-tagged TRAF4 plasmid or the Flag-tagged TLR3 plasmid or 
both, and after 24h were harvested and lysed in 200 ul of lysis buffer (25 mM 
Tris-HCl, pH 7.5, 1 mM EDTA, 0.1 mM EGTA, 5 mM MgCl2, 100 mM NaCl, 
10% glycerol, 1% NP-40, and 1X Halt Protease and Phosphatase Inhibitor 
Cocktail (Thermo Fisher Scientific Inc.). The cell lysates were tumbled at 4°C 
for 30 minutes, and were pre-cleared with 10ul of Protein A/G PLUS-Agarose 
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beads (Santa Cruz Biotechnology). The supernatant was transferred into new 
tubes and were incubated with Anti-FLAG M2 antibody (Sigma) at 4C. After at 
least 16 h, the agarose beads were added and incubated at 4C for 4 more 
hours. Then the beads were pelleted by centrifugation, collected and washed 
three times with the wash buffer (20mM Tris-HCl, pH 7.6, 150mM NaCl, 1% 
Triton X-100 Associated proteins were eluted from the beads by boiling in 40 
ul SDS sample buffer, and 20 ul of samples were fractionated by 7.5% SDS- 
PAGE. The proteins were then analyzed with immunoblotting as described 
above.    
 
Statistical Analysis    
For analysis of the real time-PCR data, the Ct values of the stimulated or 
infected samples were normalized against that of the internal control, GAPDH, 
in each experiment. All values were represented in mean +/- 10% error. 
Unpaired t-test was used, with p < 0.05 as the threshold for statistical 









Results   
 
This thesis aimed to determine whether some of the previously identified 
ubiquitin ligases (UBLs) regulating TLR3 mediated interferon (IFN) response 
regulates the stability of TLR3 protein, and thereby affecting IFN response.   
 
Ubiquitin ligases have been known to regulate innate immune pathways by 
regulating the cellular levels of many key protein components of the signalling 
pathways. However, a genome-scale view of the role of UBLs in TLR3 
mediated interferon (IFN) trancsription is not known yet. Previously 
(unpublished results), Dr. Krishnan’s laboratory performed experiments to 
identify those UBLs regulating specifically TLR3 mediated IFN production, 
through over-expression of 574 of the 614 total UBLs and their adaptors 
encoded in human genome using a cell line harboring TLR3 and a green 
fluorescent reporter (GFP) driven by human IFNb promoter, followed by 
fluorescence microscopy-based measurement of IFNb promoter activity. 
These 574 UBLs were used for the study because they were the only set of 
UBLs that were commercially available. This study identified several UBLs 
whose over expression either reduced or increased TLR3 mediated IFN 
response. The focus of this master thesis was to determine whether any one 
of these UBL that were found to regulate IFN response affects the stability of 
TLR3 protein. The underlying rationale is that any UBL that degrades or 
stabilizes TLR3 will respectively suppress or enhance TLR3 mediated IFN 
production.   
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Overview of the Experimental Strategy   
 
The proposed studies were performed in three stages:  (i) Overexpression 
screening - We selected those UBLs that affected TLR3 mediated IFN 
response (previously identified in Dr. Krishnan’s laboratory), and determined 
the effect of overexpression of these UBLs on TLR3 protein levels by Western 
blot, in HEK 293 T cells. (ii) Gene silencing - The expression of a candidate 
TLR3-degrading UBL was also silenced using small interfering RNA (siRNA), 
and assessed the effect of gene depletion on IFN response from TLR3; and 
(iii) Protein-protein interaction studies - Determine whether a selected TLR3-
degrading UBL physically interacts with TLR3.  
 
Part I: ORF Overexpression Screening to identify the UBLs regulating 
the levels of TLR3 protein.   
 
Optimization of transfection conditions for over-expression of plasmids    
 
Because the overexpression assays involved ectopic expression of both TLR3 
and the UBLs, the optimal plasmid transfection conditions for adequate TLR3 
and UBL expression was first determined. As transfection efficiency depends 
on many parameters, it was important to determine the optimal conditions to 
achieve the highest possible transfection efficiency with detectable levels of 
target protein expression.    
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Time between plasmid transfection and the assay is an important parameter. 
It has been well-established that in general the time period of 24-48 hours 
between transfection and the activity assay is best for achieving the highest 
efficiency. To determine the best time point for harvesting the cell lysate 
samples for Western blot analysis after transfection, time points of 24h, 36h 
and 48h after transfection were tested, and it was found that 24-36h gives the 
best expression levels of the transfected target proteins.    
 
Cell density is another important parameter, as a too low density will lead to 
poor cell growth and low transfection efficiency and consequently difficulty to 
reproduce the results, while a too high cell density will lead to growth arrest 
due to contact inhibition or cell death due to nutrient deletion, and as a result 
a reduced ability to take up the plasmids. As suggested by many studies, the 
highest transfection efficiency can be achieved when cells are up to 80% 
confluent. Since the cells were to be harvested 36 hours post-transfection, 0.3 
millions of HEK 293 T cells per ml in 24-well plate was chosen to be the 
seeding density because cells achieve 80% confluency after 36 hours.    
 
Overexpression of several UBLs promoted reduction of the cellular level of 
TLR3 protein    
 
Out of the 574 genes that were assayed in the genome-wide over-expression 
screens in HEK 293 T cells, more than 120 UBLs were identified to alter 
(enhance or decrease) TLR-3 mediated IFN production. 108 of these 
(selected based on the strength of the phenotype) were selected in this study 
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to investigate whether any of them increases or decreases the stability of 
TLR3 protein. For this, both TLR3 and the UBLs were co-expressed in HEK 
293 T cells for 24hr. The proteins in the cell lysates were separated by SDS-
polyacrylamide gel electrophoresis, and transferred to membranes for 
immuno-detection. The blots were probed with anti-TLR3 antibody, and also 
as loading control, with anti-GAPDH antibody. The levels of TLR3 band in 
UBLs transfected samples were compared with pLX304 empty vector (EV) 
transfected and untreated (UT) samples. The Western blot images 
corresponding to the first round of UBL ORF overexpression screening are 






















































































































































































































































































































































































Figure 6: Effect of ubiquitin ligases (UBL) overexpression on TLR3 stability. 
(a). 108 human UBLs previously found to modulate production of IFN were 
tested for their ability to alter the stability of endogenous TLR3, through an 
immunoblot-based screen. The level of TLR3 upon co-expression with UBLs 
was compared with that of the empty vector pXL304 (EV) negative control. 
GAPDH was used as the internal control. Results are representative of 2 
individual experiments. (b). Ratio of the band intensity (detected by 
densitometry, Y-axis)) of samples transfected with individual UBLs (X-axis) to 
that of samples transfected with the empty vector (EV). The intensity of the 
bands was quantified with ImageJ. The shown data is from a single round of 
immunoscreen.  
 
The TLR3 stability screening identified that a subset of genes promoted TLR3 
degradation substantially. There five genes, namely RNF20, RNF183, 
HECTD3, TRIM69, and TRAF4 that substantially reduced TLR3 protein levels. 
These five UBLs were selected for further validations and investigation. The 
primary screen was performed using over expressed TLR3. To bring 
Ratio of band intensity 
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physiological relevance and accuracy, it was next investigated whether any of 
these five shortlisted genes could affect the stability of endogenous TLR3, as 
opposed to the over expressed TLR3. These five genes were subjected to 
another round of screening, using a similar approach, in HCT 116 (intestinal) 
cell line which expresses a high level of endogenous TLR3 (unlike HEK293T 
cells which only has low levels of endogenous TLR3, prohibiting its detection). 
The result of this study is shown in Figure 7. Among the five tested UBLs, 
overexpression of only one UBL, TRAF4, notably reduced endogenous TLR3 













Figure 7. (a). Effect of overexpression of five UBLs (RNF20, RNF183, 
HECTD3, TRIM69, and TRAF4) on endogenous TLR3 in HCT116 cells. 
TRAF4 showed the most notable reduction in the level of endogenous TLR3.   
(b). Ratio of the band intensity (detected by densitometry, Y-axis) of samples 
transfected with individual UBLs (X-axis) to that of samples transfected with 
the empty vector (EV). The intensity of the bands was quantified with ImageJ. 
The shown data is from a single round of immunoscreen. 
 
Over expression of TRAF4 decreases IFNb promoter activity    
 
Because TRAF4 was identified to degrade both over expressed and 
endogenous TLR3, the role of TRAF4 was studied in detail further. Originally, 
TRAF4 was identified that TRAF4 over expression reduces TLR3 mediated 












IFNb reporter activity, indicating TRAF4 as a negative regulator of TLR3 
signalling. This experiment was further validated in this Master thesis. For 
validating the negative regulatory role of TRAF4, HEK 293 T cells were 
transfected with 200ng of TRAF4 plasmid or the empty vector (EV), and 
plasmids of TLR3 and a GFP-reporter driven by human IFNb promoter, then 
stimulated with Poly (I:C). 24 hr later, cells were imaged with a fluorescence 
microscope. As shown in figure 8, over expression of TRAF4 caused a 
decrease in the IFNb promoter activity, suggesting the role of TRAF4 as a 
negative regulator of IFN production.  
 
 
Scale bar: 150µm  
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Figure 8: TRAF4 is a negative regulator of TLR3 mediated IFN promoter 
activation. (a) Fluorescent microscopic images showing the effect of over 
expression of TRAF4 on the IFNb promoter activity. HEK 293 T cells were 
over expressed with TRAF4 or the empty vector, and then transfected with 
TLR3 and the IFNb-GFP reporter. Results are representative of 3 individual 
experiments. (b) Graphical presentation of the effect of TRAF4 on IFNb-GFP 
reporter activity. (* P < 0.05, ANOVA). EV, empty vector. The %GFP values 
are expressed after normalization with the value in EV sample. 
 
Gene silencing based assessment of the role of TRAF4 in TLR3 -
mediated IFN response   
 
Because it was observed that TRAF4 over expression both reduces TLR3 
triggered IFN response, and also promoted TLR3 protein degradation, further 
investigation were performed to determine the role of TRAF4 in TLR3 
signaling in detail. It was reasoned that if overexpression of TRAF4 attenuates 
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TLR3 mediated IFN response, then its knockdown may result in enhanced 
IFN response. For this, the expression of TRAF4 gene was silenced by RNA 
interference technology suing small interferon RNA (siRNA).    
 
Optimization of TRAF4 gene knock-down     
 
The conditions for TRAF4 gene knockdown were first optimized in HEK 293 T 
cells. The success of knock-down assays depends highly on the potency of 
the siRNA, transfection conditions, and time lapse between knock-down and 
the actual activity assay. We evaluated these conditions before proceeding to 
assess the effect of knock-down of TRAF4 on TLR3 signalling.  
 
Knockdown of the gene PLK1 is well known to cause visible cell death, and 
we used a siRNA targeting PLK1 to optimize transfection conditions of HEK 
293 T cells. PLK1 is responsible for triggering the progression of the cell cycle 
and silencing it would cause rounding of cells. Transfection of siPLK1 was 
done in HEK 293 T cells using 0.1, 0.13, 0.15 and 0.17 ul of the lipids 
DharmaFECT1, and the cell morphology was monitored every 6 hours over a 
period of 48 hours. It was found that 0.17ul of DharmaFECT 1 and 36 hours of 
after transfection gave a strong induction of cell death (as observed by cell 
rounding) indicating efficient PLK1 gene silencing.   
 
Another important determinant of a successful knock-down assay is the 
knock-down efficiency of the siRNA used. We next verified the kncokdown 
efficiency of two siRNAs targeting TRAF4. Two siRNAs, namely siTraf4-2 
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(CACCAGCACATTCGAAAGCGA) and siTraf4-5 
(AAGCTGGAAGTACAAGTATTG), were purchased and tested in an 
optimization experiment. For this, siRNAs were transfected at 50nM for 48h, 
and the cells were lysed and levels of TRAF4 protein were detected by 
Western blot. It was found that siTraf4-2 is more efficient in knocking down 
TRAF4 in HEK 293 T cells, compared to siTraf4-5.  
 
 
Figure 9: siTRAF4-2 showed a higher knock-down efficiency in silencing  
TRAF4, compared to siTraf4-5.    
 
TRAF4 gene knockdown enhanced TLR3 mediated IFNb reporter activity    
 
Because overexpression of TRAF4 causes a decrease in the cellular level of 
TLR3 and TLR3 mediated IFNb response, we hypothesized that silencing of 
TRAF4 genes will likely enhance IFNb response. To test this, TRAF4 was 
knocked down with the above-described optimized conditions and the cells 
were transfected with plasmids of TLR3 and a GFP-reporter driven by human 
IFNb promoter. After 24 hr of siRNA transfection, cells were tracked with the 
TLR3 and IFNb plasmids. 24 hrs after plasmid transfection, the TLR3 ligand 
poly(I:C) was added to the culture medium at 4ug/ml concentrations. 24 hr 
after poly(I:C)  stimulation, cells were imaged  with a fluorescence 
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microscope, using 4x magnification. The results showed that silencing of 
TRAF4 causes a notable increase of the IFNb promoter activity, further 
suggesting that TRAF4 is a negative regulator of the TLR3-mediated IFN 
production. This piece of data was consistent with that observed by TRAF4 









































Figure 10: (a). Knock-down assay showed that silencing TRAF4 causes an 
increase in the level of IFNb promoter activity. HEK 293 T cells were 
transfected with a control siRNA (siTraf4). 24 h after transfection, the cells 
were transfected with a TLR3 plasmid and a plasmid of IFNb promoter 
attached to a GFP reporter, and were stimulated by Poly (I:C) after another 
24h. Then the cells were fixed and the images were captured 24h after Poly 
(I:C) treatment. Images were captured with a fluorescence microscope.    (b). 
Graphical representation of the ratio of GFP signal to DAPI signal. Data were 
manually curated.  
 
Viral infection upregulates TRAF4 expression    
 
Since the results from the over-expression screens and the knock-down 
assay showed that TRAF4 plays a role in regulating the TLR3-mediated IFN 
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production, it was reasoned that TRAF4 is involved in regulating the immune 
response against viral infection. The expression of many of the innate immune 
pathway genes are well known to be induced by pathway activation and 
infections. Therefore, it was next investigated whether the expression level of 
TRAF4 is altered in response to TLR3 ligands. For this, we used a real virus 
(Sendai virus, a single-strand RNA virus that activates PRRs) and  Poly (I:C) 
(a synthetic TLR3 agonist made up of double-stranded RNA). HEK 293 T cells 
were either infected with Sendai virus, or stimulated with Poly (I:C) for 24h. 
RNA was extracted from the cells and the expression level was measured by 
real time-PCR. The results (Figure 11) showed that Poly (I:C) causes only a 
marginal increase in the mRNA level of TRAF4; however, Sendai virus 
infection induced a nearly 2-fold increase of TRAF4 mRNA levels. Together 
with the results shown above, we concluded that the expression level of 






Figure 11: Stimulation with TLR3 ligands increase in the expression of TRAF4 
mRNA. HEK293 T cells were treated with Poly (I:C) (20ng/ml) or infected with 
Sendai virus for 24h before the cells were harvested for q RT-PCR analysis. 
(*p < 0.05, ANOVA) Results are representative of 3 individual experiments.  
 
 
Part II: Investigating the mechanism by which TRAF4 regulate TLR3-
mediated IFN production    
 
As the over expression and RNAi knockdown experiments established TRAF4 
as a negative regulator of TLR3 signalling, it was next aimed to determine the 
underlying mechanism by which TRAF4 regulates the TLR3 pathway. 
Because TRAF4 is a ubiquitin ligase, and promotes TLR3 degradation, it was 
reasoned that TRAF4 will most likely be physically interacting with TLR3, 
leading to TLR3 degradation. So, it was investigated whether TRAF4 and 
TLR3 physically interact, using co-immunoprecipitation.     
 
Optimization of conditions of co-immunoprecipitation  
  
Results from the over-expression screens and the knockdown assay suggest 
that TRAF4 is a negative regulator of the TLR3-mediated IFN production. To 
further investigate how TRAF4 regulates the pathway, co-immunoprecipitation 
was used to determine whether TLR3 and TRAF4 interact.   
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Successful demonstration of the interaction between two proteins with co-
immunoprecipitation depends on a number of parameters, which were 
optimized before the actual experiment. First, the amount of proteins used 
was optimized by testing different amounts of proteins used: 500mg and 
1000mg of both TRAF4 and TLR3.  Another parameter tested was the dose 
and time of the proteasome inhibitor used, MG 132. It was important to 
optimized the working conditions of MG 132 treatment because it inhibits the 
functions of the proteasomal degradation machinery and thus helps to 
preserve the proteins in the interacting conformation. 5uM and 10uM were 
tested and also 6h and 24h of MG 132 treatment. It was found that treatment 
with 10uM MG 132 for 6h before lysing the cells for immunoblot analysis is 
optimum for observing the interaction of these two proteins.    
 
TRAF4 interacts with TLR3    
 
Data presented above suggest that TRAF4 targets the pathway leading to IFN 
production at the level of TLR3, so it was speculated that TRAF4 interacts 
with TLR3 physically and degrades it. After optimizing the conditions for co-
immunoprecipitation, it was proceeded to investigate this possibility. The V5-
tagged TRAF4 and FLAG-tagged TLR3 plasmids were transiently transfected 
into HEK 293 T cells and the cell lysate was used to perform co-
immunoprecipitation. The results showed that TRAF4 and TLR3 interact, 
when both proteins were ectopically expressed together in HEK 293 T cells, 




Figure 12: TRAF4 interacts with TLR3. HEK 293 T cells were transfected with 
the indicated plasmids (500ng each). Co-immunoprecipitation was performed 
with anti-V5, which was tagged to TRAF4. The immunoprecipitates were 
analysed with immunoblot with antibody against Flag, which was tagged to  




Conclusions of the results    
The results of this study revealed that some of the UBLs negatively regulate 
TLR3 pathway by promoting the degradation of TLR3 protein. TRAF4 was 
established as a negative regulator of TLR3 mediated IFN production. This 
study found that TRAF4 reduced TLR3 levels, and that TRAF4 physically 
interacted with TLR3. Thus the obtained data propose that TRAF4 induces 
TLR3 degradation through its interaction with TLR3.   
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Discussion    
 
It has been well-established that the TLR3 pathway is the major component of 
the anti-viral arm of the immune system; however our knowledge of the signal 
transduction mechanism involved in this pathway has been limited to only a 
few key molecules.  
 
Due to its importance in guarding the cells against viral infection, extensive 
research has been done to find out the regulators of the TLR3 pathway, with 
the hope of identifying potential therapeutic targets against virus-causing 
diseases. Many of the known regulators are ubiquitin ligases, which are 
responsible for proteasomal degradation of proteins, thus are important in 
recycling of cellular proteins. (Liu 2004) Many of the ubiquitin ligases that 
regulate the TLR3-mediated IFN production discovered so far target TRIF (the 
adaptor protein of TLR3) such as WWP2 (Yang, Liao et al. 2013) and Trim38 
(Xue, Zhou et al. 2012).  
 
In this Master thesis, a novel regulator of the TLR3 pathway, TRAF4, was 
found to act at the level of TLR3 protein in the signaling hierarchy. It was 
discovered in this Master’s project that TRAF4 acts as a negative regulator of 
the IFN production, mediated by the down-regulation of the cellular level of 
TLR3. TRAF4, short for Tumor necrosis factor (TNF) receptor-associated 
factor 4, is a RING domain-containing E3 ubiquitin ligase. (Kedinger and Rio 
2007) Unlike other members of the TRAF family, TRAF4 does not mediate 
signalling events through tumor necrosis factor receptors (TNFRs) and 
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interleukin-1/Toll-like receptors (IL-1R/TLRs), to activate NF-κB and MAPK 
and induce inflammatory responses. (Chung, Park et al. 2002) Its roles in 
cancer pathogenesis have been studied extensively. It has been well 
established that TRAF4 is overexpressed in breast cancer, and was found to 
be close to the ErbB2 oncogene on chromosome 17, which is closely 
associated with breast cancer. (Tomasetto, Regnier et al. 1995) It has been 
shown to activate Akt and induce TGF-beta signalling which plays a role in the 
pathogenesis of breast cancer, and has been suggested to be an oncogene. 
(Zhang, Li et al. 2014) (Zhou, Li et al. 2014)  Other than breast cancer, 
TRAF4 has also been found to be associated with other forms of carcinomas, 
such as osteosarcoma (Yao, Wang et al. 2014) and lung cancer (Li, Peng et 
al. 2013). In line with all these studies that suggest a role of TRAF4 in 
cancers, the protein has also been suggested to play a role in regulating 
apoptosis, albeit some suggest that it induces the process (Gu, Coates et al. 
2007) and some suggest that it is anti-apoptotic. (Sax and El Deiry 2003)    
 
Nevertheless, the role of TRAF4 in immunity is still poorly defined. A TRAF4 
knock-out mouse model was established to study the roles of TRAF4 in 
immunity, and it was found that the deficiency in TRAF4 does not affect the 
development of immune cells, including the proliferation of B-cell and T-cell 
populations and also the maturation of dendritic cells. Moreover, the 
responses of the TRAF4-deficient mouse towards T-cell dependent antigens 
were also not affected. The only thing found to be altered by the absence of 
TRAF4 was the reduction in migration of dendritic cells both in vitro and in 
vivo. (Cherfils-Vicini, Vingert et al. 2008) In contrast with this, it has been 
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suggested by another group that TRAF4 is a negative regulator of innate 
immunity, as it down-regulates the level of NOD2. (Cherfils-Vicini, Vingert et 
al. 2008) However, the roles of TRAF4 in immunity are not as well-studied.   
 
Before the start of this Master’s thesis project, two rounds of genome-wide 
over-expression screens were performed (unpublished results, Dr. Krishnan’s 
laboratory) and more than 120 ubiquitin ligases/adaptors were found to be 
regulators of IFN production. To test where in the pathway that these genes 
act on, 108 of these genes underwent another round of immunoblot-based 
overexpression screen for the ones that regulate the cellular level of TLR3, 
and the hits were broadly classified as up-regulators and down-regulators. 
The down-regulators were tested with another round of screen using a cell 
line that expresses a considerable level of endogenous TLR3. TRAF4 showed 
the greatest effect in lowering the level of TLR3, and was selected for further 
mechanistic studies.    
 
Based on the results of the screens, it was shown that TRAF4 down-regulates 
the cellular level of TLR3. Consistently, when TRAF4 was knocked-down 
using pre-optimized conditions, the IFNb promoter activity showed an 
increase. These support the idea that TRAF4 is a negative regulator of the 
TLR3-mediated IFN production, by reducing the cellular level of TLR3 protein.   
It was demonstrated from the qPCR experiment that the expression of TRAF4 
mRNA increases in response to Sendai virus infection. TRAF4 was shown to 
be a ubiquitin ligase that reduces the cellular level of TLR3 and IFN 
production. The increase in expression of TRAF4 in response to viral infection 
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could mean that it plays a regulatory role in the overall immune response 
elicited to eliminate the virus. As the over-production of IFN can overwhelm 
the local environment of immune cells and cause deleterious consequences 
such as septic shock, (Trinchieri 2010) TRAF4 may act as a negative 
regulator of the IFN production to maintain a relatively stable environment of 
immune cells at the site of infection to prevent excessive or unwanted 
responses while the cells try to secrete an enormous amount of IFN to clear 
the virus.    
 
After the role of TRAF4 as a negative regulator of the TLR3-mediated IFN 
production was confirmed, it was speculated that it interacts with TLR3 and 
directly degrades it by facilitating the process of proteolysis. To confirm this, a 
co-immunoprecipitation experiment was performed to check whether TRAF4 
interacts with TLR3. A band in the lane where both TRAF4 and TLR3 were 
overexpressed indicates a interaction between the two proteins. However, the 
intensity of the band is quite low, which may be due to the handling of 
samples during experimentation that led to the degradation of the two 
proteins. Nonetheless, the interaction between the two proteins was 
confirmed, but further experiments such as ubiquitination assay are required 
to prove that TRAF4 degrades TLR3, possibly through tagging it for 
proteolysis. Also, as TRAF4 is a RING domain-containing E3 ligase, it is 
highly possible that it degrades TLR3 with the action of its RING domain, and 
ubiquitination. It would be interesting to test this hypothesis using TRAF4 
mutants that lack the functional RING domain.    
 58 
The association of TRAF4 with the TLR3-mediated anti-viral response was 
previously known, as it has already been reported earlier to be a negative 
regulator of the TLR3-mediated signalling cascade acting through the 
degradation of TRIF, the adaptor of TLR3. The content of this thesis 
expanded our understanding of the role of TRAF4 in TLR3 signalling, by 
identifying that it regulates the cellular level of TLR3 directly. In the same 
report, it was also reported that TRAF4 interacts with p47phox, IRAK1, 
TRAF6, and TRIF, which are all key players downstream of TLR3 in the 
signalling cascade leading to IFN production. (Takeshita, Ishii et al. 2005) 
This further supports the idea that TRAF4 plays a role in regulating innate 
response against viral infection. However, further experiments such as in vivo 
experiments using a TRAF4-deficient mouse model are required to fully 
characterize the functions of TRAF4 in the context of innate immunity.   In 
conclusion, this study identified TARF4 as a negative regulator of TLR3 
mediated interferon response, by reducing the levels of TLR3 protein.  
Furthermore, this study paved way for future investigations on the role of 
TRAF4 in TLR3 signalling.      
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